bit.bio’s Post

We have a busy April coming up! Come to our stand to learn about our consistent, defined, and scalable hiPSC-derived ioCells™ powered by opti-ox™, including ioDisease Model Cells™, genetically matched ioWild Type Cells™, and ioCRISPR-Ready Cells™. Find out how this toolbox can help you study the impact of mutations related to Alzheimer’s and Parkinson’s disease in human CNS cells, identify novel therapeutic targets and enhance the translational relevance of your disease research and drug discovery. Explore the ioCells toolbox: https://hubs.ly/Q02r1YnD0 See all upcoming events: https://hubs.ly/Q02r1YDD0 #research #DrugDiscovery #AlzheimersDisease #ParkinsonsDisease #science #data #optiox #ioCells #ioDiseaseModelCells #microglia #HTS

Did you know that only 35% of the 2 million patients with chronic kidney disease survive the almost 5-year wait for an organ transplant? #Bioengineering and #stemcells could change this and potentially eliminate donor organ waiting lists in the future. Members of the Wellcome Leap HOPE program, including Zandstra Lab at The University of British Columbia and Lewis Lab at Harvard University, are working to end organ waiting lists and improve models for drug development globally.🌎   ▶ Play the video below to learn more about the HOPE program.   https://lnkd.in/exesscfr   #CKD #kidneydisease #innovation

#bioeuropespring discusses how the challenging public market has strained the strategies of biotechs and their investors bringing new therapies to patients. The expert panel revealed 4 key points for any new #biotech to survive the challenging and crowded ecosystem of too many new companies: 1. The science and innovation of the therapy are key to remaining relevant 15 years down the line. 2. The areas of particular interest are therapies addressing metabolic diseases, GL-P1 targets, longevity, CRISPR, and Cell Therapies. 3. It is never too early to engage and seek #venturecapital and #pharma funding and make sure you are aligned with their strategy. 4. Talk to everyone and go to all the relevant meetings and conferences. #bioeuropespring #clinicalresearch #clinicaltrials #lifescience #engagementstrategy

Only a few months ago, Marialessandra Contino and I were funded by the European Commission for the project AID-CARE (Prot. PRIN-PNRR P2022TRR3Y) validating an AI-driven workflow for developing innovative, multi-modal CB2R ligands for treating inflammation-based pathologies such as cancer, neurodegeneration, and pain. 👨🔬 👩🔬 AID-CARE aims to accelerate the drug discovery process by enabling a faster and more advantageous design-make-test-analysis cycle. While working with the AID-CARE team at CNR - ICB STIIMA-CNR Università degli Studi di Bari, we recognized the critical need for a more collaborative approach to drug discovery. Having this aim in mind, we decided to organize the First Cannabinoid Translational Science meeting to create a real occasion for confronting and brainstorming between Molecular Designers and Synthesizers, In Vitro and In Vivo Validation Experts; Prescribing Physicians and Market Experts! 😎 👉 Discover more about our project https://lnkd.in/dWjnhMDv 👉 Discover more about our symposium https://lnkd.in/d7pYCNdT #AIDCARE #CannabinoidTranslationalScience #Cannabinoids #goodscience #networking

4 key points for any new #biotech to survive the challenging and crowded ecosystem of too many new companies: 1. The science and innovation of the therapy are key to remaining relevant 15 years down the line. 2. The areas of particular interest are therapies addressing metabolic diseases, GL-P1 targets, longevity, CRISPR, and Cell Therapies. 3. It is never too early to engage and seek #venturecapital and #pharma funding and make sure you are aligned with their strategy. #lifesciences #biotechindustry #pharmaceutical #fundraising #funding #bioindustry #cellandgenetherapy #science #innovation #researchanddevelopment

🔬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐀𝐬𝐬𝐚𝐲 𝐌𝐚𝐫𝐤𝐞𝐭! 🌱 The #StemCellAssay Market is on a transformative journey, driving advancements in regenerative medicine and therapeutic applications. From groundbreaking research to innovative clinical trials, the potential for growth and discovery in this market is immense! 🌟 💡 Key Highlights: Innovative assay technologies enhancing research efficiency 🔍 Growing demand for stem cell-based therapies Expanding applications in drug discovery and disease modeling 📊 Curious to dive deeper? Check out our comprehensive market research report: https://bit.ly/3LsVzuD #StemCellResearch #RegenerativeMedicine #Biotech #HealthcareInnovation #MarketTrends #ProphecyMarketInsights

Have you seen the AMAZING SPEAKER LINE-UP for The Oligonucleotide Therapeutics Society's 20th Annual Meeting? Delegates will hear from leading experts in the field, from oligonucleotide-related industry, academia, and health authorities, and students as they present the latest updates in basic research and therapeutic developments. Here is a small sampling of this year's speakers: 🎤  Keynote Presentation by: Prof. Dr. Annemieke Aartsma-Rus, Ph.D., Leiden University Medical Center (LUMC, the Netherlands) - "From Rare to Extremely Rare: Applying Lessons Learned From Duchenne Muscular Dystrophy Antisense Oligonucleotide Mediated Exon Skipping To Developing Individualized Treatment" 🎤 Erik Sontheimer, Ph.D., UMass Chan Medical School - "Guide And Template Engineering For Genome Editing" 🎤 Cecilia Cotta-Ramusino, Ph.D., Tessera Therapeutics - "Writing DNA With RNA: Genome Engineering By Target Primed Reverse Transcription" 🎤 Xiao Wang, Ph.D., MIT - "Expanding the Alphabet and Topology of Synthetic mRNAs" 🎤 Laura Michael, Ph.D., Eli Lilly and Co. - "Identification and Early Clinical Development of Lepodisiran, a GalNAc-conjugated siRNA Targeting Lipoprotein(a) Production" 🎤 Ishir Bhan, MD, Alnylam - "Clinical Development of Zilebesiran, a Subcutaneous siRNA Targeting Angiotensinogen for Hypertension" See the Agenda at https://lnkd.in/gT9WW54Z Speaker Bios: https://lnkd.in/ggM2vEte For Information & Registration, visit: www.2024oligomeeting.com #ots24 #ots #oligomeeting #oligotherapeutics #oligonucleotide #OTS #careers #biotech #biotechnology #science #research #biochemistry #medicine #health #montreal #canada #pharmaceuticals #networking #rna #genomeediting

🌟 Exploring the Advantages of Humanized Mouse Models. Humanized mouse models offer significant advantages over traditional ones, closely mimicking human diseases and drug responses. By incorporating human cells, tissues, or genes, they provide crucial preclinical data, accelerating drug development and testing. The HUGO-Ab Mouse model stands out with low immunogenicity and high-affinity antibody production, meeting industry standards. These models enable early efficacy and safety assessments, reducing risks in human trials and broadening applications in various research fields for more effective therapeutic interventions.🐭 Share your thoughts on the impact of humanized mouse models on healthcare research! 🧬 #HUGOAB #HUGOGT #humanized #mousemodels #mice #biotech #ResearchInnovation #DrugDevelopment #HumanizedMouseModels #HealthcareResearch #Biotechnology

I am thrilled to announce that our review paper on "Engineering Circular RNA for Molecular and Metabolic Reprogramming" has been published!🎉 In this review, we explore: 🔬 the promising applications of circular RNAs (circRNAs) in diagnostics, highlighting their potential use as biomarkers and therapeutic molecules. 🧬Advances in delivery systems and gene-editing technologies, bringing us closer to harnessing their full therapeutic potential. 💡However, to fully utilize circRNAs in various disease contexts, further research and extensive clinical studies are necessary. This paper marks a significant step forward in understanding and leveraging circRNAs for future medical applications. click the link below if interested to read further: https://lnkd.in/djeURPVc #CircularRNA #Biomarkers #Therapeutics #GeneEditing #CRISPR #BiomedicalResearch

What if a patient's own immune cells could produce therapeutics 𝘪𝘯𝘴𝘪𝘥𝘦 𝘵𝘩𝘦 𝘣𝘰𝘥𝘺? With promising early insights from the first-ever clinical trial of engineered B cell therapies, we're getting closer to finding out. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🔬 Researchers are creating B cell "biofactories" that express therapeutic proteins within patients' bodies, aiming to develop safe and more efficient treatments. ⚕ Designed to treat a rare fatal genetic condition called MPS I, Immusoft's lead technology has been administered to the first human patient. 💊 Early readouts of the Phase I human clinical trial show excellent safety and pharmacodynamic effects, per Immusoft CEO Sean Ainsworth. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 Springer Nature Group 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐟𝐫𝐨𝐦 Cormac Sheridan: https://lnkd.in/embsZb4V